Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients cou...
Saved in:
Main Authors: | Brett King (Author), Emma Guttman-Yassky (Author), Elena Peeva (Author), Anindita Banerjee (Author), Linda Zhu (Author), Hua Zhu (Author), Lori Ann Cox (Author), Michael S. Vincent (Author), Rodney Sinclair (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
by: Diamant Thaçi, et al.
Published: (2023) -
Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
by: Ramírez-Marín HA, et al.
Published: (2022) -
Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
by: Kabir Sardana, et al.
Published: (2023) -
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
by: Jennifer Fu, et al.
Published: (2024) -
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
by: Samira Anderson, et al.
Published: (2024)